NUCRYST Pharma (NCST) Appoints Interim CEO
The Board of Directors of NUCRYST Pharmaceuticals Corp. (Nasdaq: NCST) announced the appointment of David B. Holtz as interim President and Chief Executive Officer of the Company and Neil Carragher as Chairman, effective immediately. Mr. Holtz replaces Thomas E. Gardner, who was Chairman, President and Chief Executive Officer. Mr. Carragher, currently lead director of NUCRYST, will assume the role of Chairman, effective immediately. Mr. Holtz will also remain as CFO.
Previously, Mr. Holtz was Vice President and Chief Financial Officer of NUCRYST.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM).
Previously, Mr. Holtz was Vice President and Chief Financial Officer of NUCRYST.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM).
You May Also Be Interested In
- Edelman Financial (EF) Says Ric Edelman Becomes Sole CEO; Ball Remains Chairman
- Green Mountain (GMCR) Director Douglas Daft Resigns, Co. Reduces Size of Board to Eight
- RIM (RIMM) Global Sales Lead Spence to Depart
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
